Newsfeed

Northwestern Medicine study provides new insights on tissue scarring in scleroderma
A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma. Fibrosis, or scarring, is a hallmark of the disease, and progressive tightening of the skin and lungs can lead to serious organ damage and, in some cases, death. The concept for new therapeutic options centers on findings made by Swati Bhattacharyya, PhD, research assistant professor in…
A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
Abstract Background Pulmonary endarterectomy (PEA) is established for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). Recently, percutaneous transluminal pulmonary angioplasty (PTPA) has been added for peripheral-type CTEPH, whose lesions exist in segmental, subsegmental, and more distal pulmonary arteries. A shift in clinical practice of interventional therapies occurred in 2009 (first mainly PEA, later PTPA). We ex…
Triple therapy shows promise for severe PAH
medwireNews: Results of a small pilot study among patients with severe pulmonary arterial hypertension (PAH) support the long-term benefits of upfront triple combination therapy, French researchers report. The 19 patients (mean age 39 years, 89% women), who had PAH in New York Heart Association (NYHA) functional class (FC) III/IV with severe haemodynamic impairment, were treated with epoprostenol (intravenous up to a maximum of 16 ng/kg per mi…
Pulmokine Awarded $1.5 Million Stage B VITA Contract to Advance Inhaled Kinase Inhibitors for Pulmonary Arterial Hypertension
Pulmokine announced it has been awarded a Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund the performance of studies that will sup…
“Denervation” of autonomous nervous system in idiopathic pulmonary arterial hypertension by low-dose radiation: a case report with an unexpected outcome
Abstract: Vasointestinal peptide metabolism plays a key physiological role in multimodular levels of vasodilatory, smooth muscle cell proliferative, parenchymal, and inflammatory lung reactions. In animal studies, vasointestinal peptide relaxes isolated pulmonary arterial segments from several mammalian species in vitro and neutralizes the pulmonary vasoconstrictor effect of endothelin. In some animal models, it reduces pulmonary vascular resista…
Bayer: First Patient Enrolled In Phase IIIb Pilot Study, RESPITE
Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), announced that the first patient have been enrolled in an open-label, multicentre, multinational Phase IIIb pilot study, RESPITE or Riociguat clinical Effects Studied in Patients with Insufficient Treatment response to PDE-5 inhibitors. The RESPITE study is designed to evaluate the clinical effects of riociguat in patients with pulmonary arterial hypertensi…
Adempas® now approved for second rare heart and lung disease
News Release Toronto, March 10, 2014 – Bayer Inc. announced today the approval of Adempas® (riociguat tablets) for treating patients with a form of heart and lung disease called pulmonary arterial hypertension (PAH).1 Adempas is currently the only treatment approved for use in two rare types of pulmonary hypertension (PH) – PAH and chronic thromboembolic pulmonary hypertension (CTEPH).1,4,5 PAH is a rare form of PH, a severe, progressiv…
FDA Clears Ventripoint VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension
SEATTLE, WASHINGTON, Mar 10, 2014 (Marketwired via COMTEX) -- Ventripoint Diagnostics Ltd. ("Ventripoint") CA:VPT +11.11% announces that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH). "We are pleased to affi…
Yale study provides a breath of hope for pulmonary hypertension patients
Most of us draw roughly 25,000 breaths a day without any thought. But for patients with pulmonary hypertension, a life-threatening increase in blood pressure in the lungs, even the smallest task can leave them gasping for air. A new study by researchers at Yale School of Medicine offers insight into the function of cells linked to this incurable and often fatal illness. Published Feb. 27 in Cell Reports, the study is the first to explore the c…
Harper Government building pan-Canadian networks to strengthen health research
February 24, 2014 – Ottawa, Ontario – Canadian Institutes of Health Research Federal Health Minister Rona Ambrose was joined by Dr. Alain Beaudet, President of the Canadian Institutes of Health Research, and Dr. Duncan Stewart, CEO and Scientific Director of the Ottawa Hospital Research Institute, to announce the launch of three pan-Canadian research networks: the Canadian Respiratory Research Network, the Canadian Stroke Prevention Interventi…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png